This article was originally published in The Rose Sheet
Executive SummaryThird quarter North America fine fragrance and functional fragrance sales grew 17% and 9%, respectively, flavors and fragrances manufacturer reports Oct. 28. Consolidated sales grew 5% on a reported basis, or 2% at constant exchange rates, to $506.2 mil. Income results included $20 mil. in pre-tax restructuring and other charges related to the sale of certain European fruit business assets to Fruitarom and closure of Dijon, France manufacturing facility. Net income dropped 17% including the restructuring charges to $51 mil. Excluding the impact of the charges, net income increased 3%. IFF anticipates low to mid-single digit sales growth for the year in local currency, or high-single digit growth on a reported basis...
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.